TokenPost topic
Biotechnology
86 TokenPost stories are tagged Biotechnology. The newest appear first.
Latest Biotechnology stories
- Heron Therapeutics Sets Nov. 9 Call to Report Third-Quarter Results
The webcast is scheduled for 8:30 a.m. ET (13:30 UTC) and will also cover recent business highlights.
· Business
- Rhythm Pharmaceuticals Shares Rise 4.2% in Friday Trading
The gain followed a 22% rise by 4:13 p.m. ET Wednesday, Nov. 4.
· Investing
- aTyr Pharma Posts $7.43 Q3 GAAP Loss Per Share, Expects Resources to Fund Operations Into Late 2028
aTyr held $50.3 million in cash, cash equivalents, restricted cash and available-for-sale investments at Sept. 30.
· Business
- Iovance Revenue Climbs 80% in Q3 as Its Net Loss Narrows
U.S. Amtagvi revenue rose about 77% year over year. Iovance remained on track to generate $410 million to $420 million in total product revenue in 2026.
· Business
- Moderna Shares Rise 10.4% in One Hour, Reaching 262.83 USDT
The quote was recorded at 7:05 a.m. ET (12:05 UTC) Friday, Nov. 6.
· Investing
- Storage, Cloud and Optical Shares Mostly Fall in Nov. 5 U.S. Premarket Trading
SK Hynix fell 3.77%, while Coherent gained 3.58%; four of six named stocks in the biotech group also rose.
· Investing
- United Therapeutics Acquires Pfizer Royalty Interest Tied to Ralinepag
The deal involves ralinepag, an experimental lung disease therapy, and was disclosed with the company’s third-quarter 2026 results.
· Business
- Sanofi Decides to Stop Studies of Nurix-Partnered Experimental Drug
Nurix Therapeutics shares extended losses from after Tuesday’s market close into Wednesday premarket trading.
· Business
- United Therapeutics Q3 Revenue Rises 4% as Net Income Falls 24%
Diluted earnings per share declined 20% to $5.71, while research and development expense more than doubled to $279.2 million.
· Business
- Rhythm Pharmaceuticals Shares Rise 22% in Wednesday Trading
The shares were up 22% by 4:13 p.m. ET on Nov. 4.
· Business
- Ultragenyx Sets 2027 Expense Targets as It Winds Down GTX-102
The company plans to reduce its workforce by about 20% and reaffirmed its forecast for full-year GAAP profitability in 2027.
· Business
- Peptide boom exposes evidence gaps as drug development and prescribing markets draw interest
Tirzepatide sales reached nearly $44 billion in the first nine months of 2026. Andreessen Horowitz examines evidence gaps in unapproved peptides and prospects for regulated drugs and prescribing businesses.
· Insights & Views
- PTC Therapeutics Board Authorizes Up to $500 Million in Share Repurchases
Purchases may use several methods, including open-market transactions, and will depend on market conditions and management’s discretion.
· Business
- Syndax Projects Revuforj Could Exceed $2 Billion in Peak U.S. Net Revenue
Revuforj generated $60.7 million in third-quarter net revenue, up 90% year over year. Syndax’s peak estimate includes anticipated frontline indications.
· Business
- Molecular Partners Says $69 Million Can Fund Operations Into Late 2027
The company plans to cut up to 55 positions by the second quarter of 2027 as dosing for MP0712 continues.
· Business
- Formation Bio Launches Fund With $600 Million in Capital Commitments
The company plans to acquire or license 10 to 15 programs over three to five years, focusing particularly on Phase 1 and Phase 2 candidates.
· Business
- Alnylam Q3 Revenue Rises 17% to $1.46 Billion as Net Product Revenue Jumps 52%
Diluted non-GAAP EPS was $16.26. Alnylam reaffirmed its 2026 net product revenue forecast of $4.7 billion to $5.1 billion.
· Business
- Bicycle Therapeutics Q3 Revenue Climbs 190.4% to $34.06 Million
GAAP EPS was a loss of $0.15, $0.33 above estimates. Revenue exceeded estimates by $21.86 million.
· Business
- INmune Bio Sets $4.5 Million Registered Direct Offering and Warrant Placement
The agreement pairs a sale of 3 million common shares with unregistered warrants covering up to 3 million additional shares.
· Business
- Rapport Therapeutics Shares Drop 24% After Pricing About $355 Million in Offerings
The package includes two common-stock transactions and $150 million in convertible senior notes due in 2032.
· Business
- Kiniksa Raises 2026 ARCALYST Revenue Outlook to $1.045 Billion-$1.050 Billion
Third-quarter ARCALYST net product revenue was $286 million, up about 58% from a year earlier. Kiniksa expects KPL-387 trial data in the second half of 2027.
· Business
- Actuate Therapeutics Prices $11 Million Stock-and-Warrant Offering
Investors will buy two shares and one warrant together for $0.71. The offering is expected to close Oct. 28, subject to customary conditions.
· Business
- SL Science Posts $1.39 Million in First-Half Revenue, Up 22.8%
The unaudited six-month results showed a $2.16 million net loss and a gross margin of 40.2%.
· Business
- Nautilus Biotechnology, Inc. to Report Q3 Results Before Market Open Oct. 27
The consensus estimate calls for a loss of $0.14 per share and $210,000 in revenue.
· Business
- Wave Life Sciences Sets Oct. 27, 2026 Q3 Review, Expects WVE-006 Data in Q4 2026
Cash, cash equivalents and marketable securities totaled $490.6 million at June 30, with the balance expected to fund operations into the third quarter of 2028.
· Business
- Azitra Shares Show 101% Gain in Snapshot as Company Reports Skin Data
A reported $1.44 intraday quote compared with a $0.715 split-adjusted previous close. Azitra also said it would pause sales through its at-the-market program.
· Investing
- WuXi AppTec Raises 2026 Guidance as Nine-Month Revenue Rises 38.6%
Adjusted non-IFRS diluted EPS was RMB 6.21, while backlog for continuing operations reached RMB 76.74 billion at Sept. 30.
· Business
- YZi Labs Names Four Students to Its First Atlas Scout Cohort
The students will help evaluate early-stage startups in Web3, AI and biotechnology, while YZi Labs retains final investment authority.
· Business
- Gilead Agrees to Acquire PepStar’s Oral IL-23R Program for $1.275B
Lead candidate HCXT-2001 is in Phase 1. Closing is expected in the fourth quarter of 2026, subject to customary conditions.
· Business
- Kevin Weil’s Warp Sciences Raises $215 Million for AI Drug Research
The startup plans to automate molecule testing, a drug development stage traditionally handled by Chinese firms.
· Business
- TriGemX Bio Announces TCGX Business Combination With Projected $600 Million Equity Value
The proposed transaction could generate about $246 million in gross proceeds before costs if TCGX public shareholders do not redeem their shares.
· Business
- EU Panel Again Declines to Endorse Omeros Transplant Therapy
Omeros had also failed to secure the panel’s backing in an earlier review this year.
· Regulation
- AstraZeneca and insitro Announce AI Drug Discovery Deal Valued at Up to $1.5 Billion
The two companies plan to identify drug targets together and advance them.
· Business
- Nasdaq 100 Futures Fall 1.1% as U.S. Premarket Shares Diverge
Dow futures rose 0.3%, while S&P 500 mini futures slipped 0.3%. Optical communications shares fell as biotechnology stocks mostly advanced.
· Investing
- AI-Designed Enzymes Cut Selected Protein Sequences in Lab Tests
Two studies tested cysteine- and zinc-based designs, including enzymes that cut selected sequences in TDP-43 and amyloid-beta.
· Technology
- MaxCyte Preliminary Q3 Core Revenue Rises 26% to About $8.1 Million
The preliminary figure covers MaxCyte’s core business for the third quarter of 2026.
· Business
- Vir Biotechnology Shares Rise Nearly 10% in Premarket After Gilead Deal
Gilead will use Vir’s PRO-XTEN platform to discover and develop cancer drugs under an agreement valued at up to nearly $1.9 billion.
· Business
- Arrowhead Shares Rise After Alzheimer’s Drug Trial Data
Arrowhead Pharmaceuticals said early-stage data for ARO-MAPT led it to declare initial clinical validation of its TRiM delivery platform.
· Business
- Pinnacle Food Group Shares Rise 63.6% as Lab Milestone Draws Focus
Pinnacle Food Group said its subsidiary completed its first 5-liter fermentation of recombinant human lactoferrin. The stock’s $4.37 upper Bollinger Band is the next technical reference.
· Investing
- Giraffe Bio Raises $6.4 Million to Improve Copper Recovery
The startup develops mine-specific biomolecules designed to recover more copper during flotation while reducing reliance on toxic chemicals.
· Business